Message from the President

As my term as ISOPP President comes to an end, I would like to reflect back upon what ISOPP has accomplished over the past two years. I think we have moved forward, but still have much to do if we are to accomplish ISOPP’s goals.

ISOPP has a fresh new image with its new logo. ISOPP has a new and active website that allows members to communicate and interact with each other. The website will be improved further and if it’s to succeed, then all ISOPP members must make using the website a part of their daily routine. The ISOPP Newsletter is now published quarterly and will soon be published electronically. The website and the Newsletter are products from the ISOPP Publications Committee. This committee was able to provide travel support to some ISOPP members through a website competition. Projects like this will certainly be continued in the future.

ISOPP’s committee programs continue to grow and support the needs of ISOPP members. The ISOPP Research Committee awarded over US$12,500 for several research projects. Additional research grants are included in the current ISOPP budget so we hope that members will take advantage of this program to support their research projects. The Education Committee is hard at work finalizing all of the details for ISOPP IX in Turin, Italy. I am sure you will be satisfied with the outstanding program they have put together. And while putting together this meeting together takes considerable time and effort, this committee will be working on other efforts throughout the year that will help ISOPP members.
The Membership and Finance Committee has done a tremendous job in developing the ISOPP recognition program. I am happy to say that we will have members recognized at the opening ceremony at ISOPP IX for all ISOPP award categories: The Helen McKinnon Award; ISOPP Achievement Award; and, Fellow of ISOPP. We will also have members receiving travel grants through this committee’s efforts. And last, but certainly not least, the ISOPP Standards Committee is very busy gathering safe handling standards from all around the world to begin to compose the first draft of an ISOPP Standard for Handling Cytotoxic Agents. I am hopeful that this will be completed and approved by the end of the year as the first officially endorsed standard from ISOPP.

As Editor of JOPP, the Society’s journal, I am pleased to report that we are receiving more articles for publications and have brought JOPP back to a proper publication schedule. I continue to receive very positive comments from authors about how the submissions are reviewed. Although greatly improved, we continue to work with our ISOPP management company, CMC International, to resolve any problems with JOPP distribution. As a pilot study we have begun translating the abstracts from JOPP into several languages, German, French, Spanish, and Italian, to increase the value of JOPP for ISOPP members who do not speak English as their primary language.

While I think we have accomplished and improved upon many ISOPP goals, I think there are still some basic issues that need to be addressed. The ISOPP Constitution and Rules need to be reviewed to be sure they still represent all interests within ISOPP. If ISOPP is to have a stable membership base, I think procedures where ALL members have input into potential changes need to be developed. Probably most importantly though, ISOPP needs to develop a strategic plan to recruit and retain members. ISOPP needs to continue to explore, through its Chapters and Affiliates program, relationships with big and small groups of oncology pharmacists throughout the world to decide how ISOPP can support these supports and how these pharmacists and groups can help support ISOPP. And, I think most importantly, ISOPP needs to continuously survey its members to find out what they want from ISOPP and then develop a program to meet these needs.

I have thanks to give to many people who have provided their support to achieve the ISOPP goals and programs mentioned in this editorial. The Secretariat worked very hard, sometimes against very short deadlines, to review and approve all of the new programs for ISOPP. For this, I would like to thank all them – Graham, Thomas, Bob, Jill, Saad, Franca, and Camille – thank you on behalf of ISOPP. The Committee Chairs deserve special recognition as they are volunteers to their positions – Johan, Robbie, and Tom – thank you for work with the ISOPP Standards Committee; Helen – thank you for stepping up to the plate (as we say in America) and contributing your time to help develop the ISOPP IX program as ISOPP Education Committee Chair. I would like to thank Graham for developing the ISOPP Research Awards program as ISOPP Research Committee Chair. A very special thanks goes to Terry for pushing the ISOPP Recognition program forward. And, Jude deserves extra special thanks for developing the new ISOPP website. I think this will become one of the most
important – if not THE most important – member benefit. And on that same note, kudos to Jill for doing double duty as Secretariat Member and Newsletter Editor as the Newsletter is another important member benefit. So, from ISOPP and me personally, thank you for all of your efforts to make ISOPP the best oncology pharmacy society in the world.

To the new Secretariat, some of whom have already been decided – Graham, Saad, Thomas, and Jill – I suggest patience and perseverance in your quest to meet the needs of ALL ISOPP members. Use what you have learned over the past two years (or more) to better the society. As we have experienced, there will be tough choices to make – but make them with ALL members in mind.

My time as ISOPP President has taught me many things about myself and the profession. It has created friendships that will last forever, and I see this as an unwritten benefit of being an ISOPP member – to make friends from colleagues around the world all because we share a similar interest – to improve the care of people suffering with and affected by cancer.

Warmly,

Barry

Email: bgoldspiel@nih.gov
Phone: USA 301.496.5869
FAX USA 301.496-0210
Final Update on ISOPP IX

On behalf of the Scientific and Organising Committees, I’m very happy to invite you to attend ISOPP IX which will be held in Turin, from 14th to 17th April. The symposium is hosted by ISOPP and the Italian Society of Health System Pharmacy (SIFO). Jill Kolesar, Helen Leather and I together with the members of the Scientific Committee have worked very hard in preparing the program which covers many aspects of our practice and, I am sure will meet your needs.

The symposium represents a unique opportunity for meeting experts on diverse topics. It will open with two key lectures which will give us an overview on current research and clinical practice in oncology. Prof. Maurizio Tonato from Perugia, past President of ESMO and Piero Pelicci from the Oncological European Institute in Milan will present these two important topics.

The following days will be filled with plenary sessions, parallel sessions and meet the expert sessions during which clinical topics, translation research and oncology pharmacy practice will be developed. The latest updates about the most common diseases, from colon cancer to non small cell lung cancer and supportive care and pain control therapy will be discussed with expert and famous clinicians such as Prof. Giaccone, Sobrero, Tura, Roila, Ripamonti, Luca Gianni, just to name a few. Many practical and management aspects like how to supply an oncology Pharmacy Service which will cover two sessions enabling you to develop basic and higher professional competency and skills together with sharing experiences with colleagues coming from all over the world. Other topics include how to prevent and manage errors in daily practice, drug interactions and safe handling. A round table discussion on implementing new therapies will look
at the pharmacists' role when new and expensive drugs are placed on the market, examine patient expectations, oncologists' choices and which criteria are used by the regulatory authorities in the light of resources available. What are the problems concerning access to these high cost therapies?

There will also be small and working groups on diverse topics such as career planning and clinical research. This symposium offers a rich program, a unique opportunity for comparison and sharing experiences, learning, knowing, meeting famous experts and, why not, enjoyment!

At the end of the meeting there will be a fun session not to be missed! And all of this will take place in the beautiful city of Torino!
Visit our website www.isopp.org for further details of scientific programme, social events, sightseeing or visit www.isopp2004@mzcongressi.com for organising aspects.

I'm looking forward to meeting you in Turin!

Franca Goffredo
ISOPP IX is just a few days away!

Check the website for the final programme – it’s not too late to register. This meeting is the highlight in the ISOPP calendar providing both educational and social opportunities. This year we have 69 poster abstracts from people sharing their work with us. These abstracts are from the following countries:

- Australia 8
- Belgium 2
- Canada 10
- Czech Republic 2
- France 4
- Germany 4
- Italy 11
- Poland 1
- Russian Federation 1
- Slovenia 1
- Spain 11
- Sweden 1
- Thailand 1
- United Kingdom 8
- United States 4

Make sure you leave plenty of time to read the posters!
STOP PRESS!
JOPP Abstracts Translated

The editor of JOPP, Barry Goldspiel recently received this email from a satisfied JOPP contributor:

Dr Jiménez and I would like to congratulate The Journal of Oncology Pharmacy Practice on the accuracy of translation into Spanish of abstracts from JOPP volume 9. It is not very common to find such an excellent translation in other journals of Pharmacy.

Yours sincerely
Asunción Albert Marí (Servicio de Farmacia Hospital Universitario Dr Peset Valencia SPAIN)
Editorial

ISOPP IX will soon begin. Many thanks to Franca Goffredo, Jill Kolesar, Helen Leather, the Scientific Committee and SIFO for organizing and hosting this symposium. Many, many hours of behind the scenes work is required for any successful meeting and without this volunteer effort ISOPP members would not have the opportunity to meet, learn and share their work. I am really looking forward to ISOPP IX!

The ISOPP Elections have recently taken place and I hope that you voted for your preferred nominees. I ran for a position that no-one else nominated for so I am now the ISOPP Secretary. I will join Graham Sewell (President), Saad Othman (President –elect), Thomas Garms (Treasurer) and four other members who will be announced at ISOPP IX. Please contact me at any time with suggestions to put before the Secretariat.

It is with great pleasure that I received my JOPP journal this week. What a great step forward the Editorial Board has taken to have abstracts translated into several languages thus making the Journal even more attractive to our international membership.

Contact me at jillian.davis@austin.org.au or via the website.

Cheers

Jill
Website Competition winners

Quotes from the following three members who won free registration for ISOPP IX in the recent competition:

Sarah Jennings (Canada) said "Thanks for the great news - I'm stunned!"

Suzanne Taylor (Canada) said "Yippee"

Stavroula Kitir (Cyprus) said "Thanks a lot, I can't believe it that I am one of the three winners and the only one from Europe. Thanks a lot, I am so excited."
**ISOPP Website Poll results**

What do you think of the new ISOPP Home Page?

<table>
<thead>
<tr>
<th>Option</th>
<th>Number of votes</th>
</tr>
</thead>
<tbody>
<tr>
<td>It is clearer and easier to follow</td>
<td>84%</td>
</tr>
<tr>
<td>I preferred the old one</td>
<td>2%</td>
</tr>
<tr>
<td>I do not mind either way</td>
<td>11%</td>
</tr>
<tr>
<td>I have other ideas and will contact you</td>
<td>4%</td>
</tr>
</tbody>
</table>
JOPP Best Paper Awards

Barry Goldspiel, ISOPP President and Editor, Journal of Oncology Pharmacy Practice (JOPP), is pleased to announce the JOPP Best Research and Best Practice Papers for 2001 to 2003:

Best Research Paper

External contamination of vials containing cytotoxic agents supplied by pharmaceutical manufacturers.

Best Practice Paper

Development of procedures to address health and safety issues in the administration of gene therapy within the clinical setting.

The winners will receive a US$500 grant and a plaque which will be presented at the opening ceremony of ISOPP IX in Turin, Italy.

Please congratulate these authors for their excellent contributions to JOPP and support of ISOPP.
Invitation from ISOPP Standards Committee: Mark your ISOPP IX Diary Now!

The ISOPP Standards Committee is hosting a workshop at ISOPP IX in Turin on Saturday April 17th 1100 – 1215. The committee has been busy over the last 12 months collecting data on existing Oncology Pharmacy Practice Standards and with your help is working towards the production of ISOPP Practice Standards.

So far 15 standards have been reviewed by the committee and the information has been entered into a database. These data have now been analysed. In total, 29 topics including the safe handling of cytotoxics, technical equipment, transport, administration and clinical pharmacy have been examined. An overview of the results, and the similarities and differences between standards will be presented and discussed at the workshop. If this interests you, please come and join us. Bring along any Standards you use at home.

We will also be having a Standards Committee meeting on Wednesday 14th April at 0900 – anyone interested in joining the committee is warmly invited to attend. See you there!

Johan, Robbie, Tom
ISOPP Standards Committee
Jude: Dear Irena Netikova. If you have not visited the ISOPP website before, or recently - why not try it today at www.isopp.org. We have a NEWS section that is regularly updated. Currently there are announcements about:- Candidates for the next Secretariat election; winners of the Website Competition for free registrations at ISOPP IX; information on how to get a password if you have NEVER logged in before; Preliminary Program for ISOPP IX with registration and Housing Forms. There are many interesting sections on the website after you have logged in - such as a Discussion Group where you can post questions of any kind, or answer questions others have asked; a list of ISOPP members with their emails to see who in your country or around the world is a member; an Education Centre with Links. Go on - try logging on to www.isopp.org TODAY!

Warm regards Jude

Irena: Thank you for your warm email. I visit ISOPP website almost every week. I had
some problems with my login because of the Czech PC keyboard, but today I have been successful, and I hope that I will have a username and password soon. The ISOPP website is very interesting and well performed. I am sending you the Website Survey and hope it helps you. There are only a few ISOPP members in the Czech Republic. But every pharmacist who calls me for advice in oncology pharmacy (mostly their hospital are going to perform centralised cytostatic reconstitution) gets information about ISOPP’s website. Language is our problem (especially for middle-aged people), and not understanding written English. Even more difficult is understanding spoken English and writing correctly. My younger colleagues are much better in English than I am and I suppose that in the future our oncology pharmacy will be without communication problems.

Jude: Thankyou very much for this - it is very useful to get your feedback. Your English seems good to me. Can you imagine me trying to speak or write Czech? NO! I can manage a little French and German and a VERY little Italian (such as gelati, spaghetti!) So I congratulate you on your efforts. Are there many oncology pharmacists in Czech Republic?

Irena: The best known person in Czech oncology pharmacy is Martin Benes. Martin, Chief Pharmacist of the first hospital pharmacy in our country with central cytostatic preparation, has fostered oncology pharmacy for more than 10 years. I like my job very much and take interest in oncology care and research from the pharmacist viewpoint.

Jude: I know Martin well, as we were both on the ISOPP Secretariat together and I was involved with ISOPP VII (in Prague and Chaired by Martin). Do you get a chance to do any clinical pharmacy?

Irena: I have little opportunity to do clinical pharmacy because right now I am concerned with the central preparation of cytostatic drugs, research and some teaching activities. I started to work in the Oncology Clinic in our hospital (General Teaching Hospital of Charles University, Prague) 15 years ago. I used to take part in clinical rounds and counselling patients about drugs, but I felt I didn’t have enough experience and so the main part of my job was in the lab. We performed oestrogen/progesterone assays to support decisions for hormonal therapy in patients with breast cancer, and did tumour marker assays for following treatment efficacy or predicting early relapse. It is not usual to do clinical pharmacy in our country. I have made very close relationships with many of our oncologists and now I am responsible for preparation of cytotoxics for their patients. I take part in supportive care solutions (mucositis, neurotoxicity after ifosfamide, extravasation etc) and I am a member of the Oncological Clinic Research Team with a responsibility for chemo-resistance assays and for supporting individualised chemotherapy for patients. I don’t work directly with patients. I suppose that the main reasons are the low numbers of pharmacists in our hospitals and poor communication with other clinical staff. Clinical pharmacy seems very interesting to me and some of my colleagues and we hope to have an opportunity to be more patient focused in future.

Jude: Will we see you in Turin?
Irena: Certainly, I have a poster accepted and I am looking forward to the meeting very much!
An overseas pharmacy study visit - one of the benefits of ISOPP membership

Have you considered visiting with your ISOPP colleagues in another country to gain experience of the varying practice and training?

We all know Oncology pharmacy is a specialty field and practitioners working in it require specialised knowledge. Training and practice varies from country to country and as Helen McKinnon found in 1986 a practitioner can gain valuable experience visiting with colleagues in other countries. One of the benefits of ISOPP membership is the opportunity to network with other members around the world and gain this experience.

In mid 2003 Annette Junker, a German ISOPP member decided she would like to take advantage of such an opportunity. She contacted Terry Maunsell, an Australian ISOPP member with her idea of spending two weeks visiting Australian hospitals. As distances in Australia are very large it was decided that it most feasible for her to spend the two weeks in the Sydney area. Terry planned a schedule which would allow Annette to visit a number of Sydney and regional hospitals. The hospitals were: Royal Prince Alfred, Sydney Children's, Royal North Shore, Gosford and Wollongong.

While reconstitution and safe handling practices were very similar to those in Germany the major differences noted from practice in Germany were:

- The clinical pharmacy practice
- The role of the oncology and haematology pharmacists in the oncology and haematology teams.
- The involvement of the pharmacist in clinical trials.

The flow of knowledge and experience was not one sided. The Australian pharmacists welcomed the opportunity to learn from the experiences of their German colleague. Indeed on one particular day at Royal Prince Alfred Hospital, Annette’s extensive knowledge and experience was able to solve a problem for the young pharmacists in the oncology unit.

In addition to the educational aspect of the visit, Annette was able to take advantage of the wonderful Sydney summer weather and include some sightseeing of the region and experience the Sydney restaurants. She was also seen surfing at the famous Sydney beaches of Bondi, Manly and Coogee!
Such an exchange is thoroughly recommended by all parties.

Terry Maunsell

p.s If you are attending ISOPP 1X in Turin visit the poster exhibition and see Terry and Annette’s poster about the visit.

Royal Prince Alfred – Day Chemotherapy Centre
Terry and Annette hard at work during the visit
New Members

**Australia:** Kerrianne Grundie; Mair Humphries; Sarah Jones; Rachel L. Nixon; Jim Siderov; Moi-Yap Soh; Ryan Watts
**Austria:** Kerstin Rigler-Dinhopel
**Canada:** Karen Chuk; Anna Granic; Laurel Kovacic; Pamela Ng; Lisa A. Rambout; Paola Reynolds; Isabelle Savoie
**Czech Republic:** Ilona Vankova; Petra Vasutova
**Denmark:** Anna Adelfred
**Germany:** Ute Barths; Jutta Flür; Dieter Hübl; Brigitte Hübner; Petra Janssen; Gerhild Knuth; Bianca Köster; Peter Kraus; Birte Lohnhard; Kirstin Neidhart; Wioletta Olech-Sekular; Anke Ritter; Claudia Siegers; Ulrich Sommer; Andrea Wohlrt; Ilka Ziegler
**Ireland:** Fionnuala King
**Italy:** Felice Musicco
**Malaysia:** Birinder Kaur
**Malta:** Fiona Fenech
**Poland:** Agnieszka Jarmolowicz
**South Africa:** Elaine Edelstein
**Spain:** Carlos J. Andrés; Pilar Gonzales
**Sweden:** Malene Bokinge; Eva Rämme
**Thailand:** Apirom Laocharoenkeat; Pattama Natrujirote; Surasit Vatcharasukpo; Amornrat Vijitleela
**United Kingdom:** Nanna Christiansen; Xandra Neuberger; Sally Punter
**USA:** Debbie Drajer; Robert Fincher; Damian May; Catherine Mondon; Lawrence Terenzi
Board Certification in Oncology Pharmacy: The Foreign Candidate’s Experience

In 2001 we were each awarded a specialisation Grant to undertake the Board of Pharmaceutical Specialties (BPS) examination in Oncology. These grants were administered by the Research and Development Grants Advisory Committee of the Society of Hospital Pharmacists of Australia (SHPA).

What is the BPS?
The BPS is an independent agency which provides recognition for specialist pharmacists in the United States of America. Since 1996 Oncology Pharmacy has been recognised as a specialty and there are currently 384 Board Certified Oncology Pharmacists.

Can Non US Pharmacists Become Board Certified?
Yes. Although certification is directed mainly at those practicing in the USA, pharmacists trained and licenced to practise outside the USA may sit the examination and become Board Certified. There are presently 36 Non US Board Certified Oncology Pharmacists practising in Australia (6), Canada (5), Singapore (4), Saudia Arabia (1), Spain (14) and the United Kingdom (6). Eligibility requirements to sit the exam and a full candidate’s guide can be obtained from the BPS website at www.bpsweb.org.

What Study Resources Are Available?
Pharmacists residing outside the US may access an on-line preparatory course offered by The American Society of Health-System Pharmacists (ASHP) and the American College of Clinical Pharmacy (ACCP). Access to the course may be purchased from the ACCP website www.accp.com. The course provides comprehensive overviews on a large number of tumour types and is oriented towards patient cases and problem solving. A number of other oncology review products are available from the ASHP website www.ashp.org. There is also a live 2 day course run each year in the United States. In 2003, for the first time, ASHP and ACCP joined forces to run a joint Oncology Review Course.

Is the Oncology Review Course Worth Attending?
We attended the ASHP Oncology Review Course held in Orlando, Florida, in May 2002. Attendance at such a review course is highly recommended for those contemplating sitting the BPS Oncology exam. This course helped us to determine the depth of knowledge that is required to pass the exam, and also to identify areas where we may be deficient. The course was run by a faculty of experienced practicing oncology pharmacy specialists, and the comprehensive notes
from the course are an invaluable source of information. These notes include an overview of many common cancers, their staging and treatment, plus sections dealing with cancer screening and prevention, drug development, pharmacogenomics and statistics. In addition, the notes cover some of the American legislation and administration required for the exam.

Is It More Difficult for Foreigners?
Yes. Overseas candidates are clearly disadvantaged in that they must be familiar with various regulatory affairs in the US. There is no exemption. This includes the FDA procedures for acquiring investigational agents outside of a clinical trial, Accreditation processes in the US, Managed Care Organizations, and knowledge of Medicare and Medicaid. Clinical practice differs considerably from country to country, and candidates must be very familiar with the numerous current American guidelines applicable to the specialty. In the case of Oncology this includes the guidelines published by the National Comprehensive Cancer Network (NCCN) [www.nccn.org](http://www.nccn.org), the American Society of Health-System Pharmacists (ASHP), the American Society of Clinical Oncology (ASCO) [www.asco.org](http://www.asco.org) and the Infectious Diseases Society of America (IDSA) [www.idsociety.org](http://www.idsociety.org).

The units of measurement used in the United States may also be unfamiliar to foreign candidates, but a conversion chart is provided during the examination.

Another problem for foreign candidates may be isolation. Often only one or two pharmacists in a country may be studying for the exam and so the support of a study group is missing.

Is It All Worth It?
Having both passed the exam we can say yes! We both gained an enormous amount of knowledge and our confidence to practice competently as oncology pharmacists has been enhanced. We can now more fully contribute to the multidisciplinary care of our patients.

Alison Cavill, Robert McLauchlan. AUSTRALIA
British Columbia Cancer Agency (BCCA) Annual Cancer Conference Report

The British Columbia Cancer Agency (BCCA) held its annual cancer conference on November 27-29, 2003, in Vancouver, BC, Canada. This yearly event gives many British Columbians an opportunity to network and learn from each other, as regional and provincial leaders meet to discuss all aspects of cancer control. Over 700 delegates were eager to share knowledge about cancer research, prevention, screening, treatment, administration, and technology.

The venue was the Fairmont Hotel Vancouver, which many readers will remember from ISOPP VIII. On Saturday, November 29, the hotel was full of clinicians taking part in profession-specific sessions. Nearly 60 pharmacists gathered for the day. Our grumblings regarding the 0700 start time were soon put to rest by the wonderful breakfast provided and the chance to chat with colleagues from across the province.

Firstly, a review of alemtuzumab was given by Lynne Nakashima. Lynne is an ISOPP member, an ISOPP Publications Committee member, and this year’s president of the Canadian Association of Pharmacy in Oncology (CAPhO). Next, Joan Fabbro reviewed the bisphosphonates, some recent literature supporting the use of zoledronic acid, and a cost comparison of zoledronic acid and pamidronate. There is still no satisfactory resolution to the competition between these two drugs.

ISOPP member Dana Cole gave an engaging talk on the importance of smoking cessation. We learned that tobacco kills more people than AIDS, TB, maternal mortality, murder, and suicide combined. We learned that, in Canada, deaths from tobacco are equivalent to a Boeing 747 crashing daily. We also learned Dana’s tips on motivational
interviewing, and heard about the smoking cessation program she has implemented in northern BC.

We were privileged to have Robin O’Brien review hormonal therapies in breast cancer. Robin is well-known in Canadian pharmacy circles as an expert on breast cancer, natural medicines, and marijuana use (legal use, of course).

We enjoyed lunch in the Pacific Ballroom, and took in manufacturer’s exhibits and poster presentations. Readers may be aware that scientists at the BCCA’s Genome Sciences Centre were the first to sequence the SARS virus. Having colleagues at the Genome Sciences Centre, the Terry Fox Laboratories, and the University of British Columbia certainly increased the calibre of our poster presentations! Clinicians were awestruck by the discoveries being made in the basic sciences.

After lunch, Leela John discussed irinotecan, oxaliplatin, and capecitabine, reviewing both place in therapy and management of side effects.

ISOPP member Susan Walisser had the rather unpleasant task of speaking to us mid-afternoon, when we were all a bit drowsy. Nonetheless, her review of future therapies for colon cancer kept us all awake. The talk was titled “Weaving the Threads of the Past into the Innovations of the Future” and was interspersed with photos of beautiful quilts Susan has made. Saira Mithani gave a comprehensive overview of lung cancer in BC, and specifically discussed pemetrexed, gefitinib, and topotecan.

Finally, Sue Aro led a fun-filled session on adult learning. Sue is the coordinator of the pharmacy technician program at Vancouver Community College. She gave us some neat facts about the human brain, told us the ways in which adult learning differs from childhood learning, and facilitated an interactive session allowing us to determine our own learning style. Naturally, this was followed by a great deal of analysis… “Oh, that’s why I can’t work with so-and-so… I’m a converger, and she’s a diverger.”

Readers may access slide shows for all of these presentations on the BCCA website. Just go to www.bccancer.bc.ca, click on Annual Cancer Conference 2003, then click on Pharmacy.